Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.57 USD | -0.28% | +11.56% | +141.22% |
May. 02 | Transcript : Cardiff Oncology, Inc., Q1 2024 Earnings Call, May 02, 2024 | |
May. 02 | Cardiff Oncology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Financials (USD)
Sales 2024 * | 390K | Sales 2025 * | 66.67K | Capitalization | 160M |
---|---|---|---|---|---|
Net income 2024 * | -45M | Net income 2025 * | -57M | EV / Sales 2024 * | 409 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 2,394 x |
P/E ratio 2024 * |
-3.65
x | P/E ratio 2025 * |
-3.37
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.33% |
Latest transcript on Cardiff Oncology, Inc.
1 day | -0.28% | ||
1 week | +11.56% | ||
Current month | -18.12% | ||
1 month | -32.39% | ||
3 months | +104.00% | ||
6 months | +195.04% | ||
Current year | +141.22% |
Managers | Title | Age | Since |
---|---|---|---|
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
James Levine
DFI | Director of Finance/CFO | 53 | 21-07-11 |
Tod Smeal
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-01-10 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Armitage
BRD | Director/Board Member | 77 | 20-04-21 |
Gary Pace
BRD | Director/Board Member | 76 | 20-04-21 |
Mark Erlander
CEO | Chief Executive Officer | 64 | 13-03-03 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 3.57 | -0.28% | 336,262 |
24-05-14 | 3.58 | +2.87% | 844,336 |
24-05-13 | 3.48 | +2.65% | 341,899 |
24-05-10 | 3.39 | +0.30% | 471,847 |
24-05-09 | 3.38 | +5.62% | 1,118,376 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+141.22% | 160M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- CRDF Stock